Affymetrix - hochspekulativ aber kurzfristig interessant - 500 Beiträge pro Seite

[Waldbauernbub]

Affymetrix ist ja gewaltig unter die Räder gekommen nach der Gewinnwarnung. Momentan unberechenbar, aber ein mögliches Szenario ist eine Erholung des Kurses. Die letzten paar Tage stabilisiert sie sich bei 18 USD, auch findet sie dort immer wieder starke Nachfrage - die letzten paar Tage kam zu Börsenschluß immer Kaufdruck auf - hat den Nasdaq-Biotechindex outperformed - dieser steht in der Stochastik widerum kurz vor einem Kaufsignal.
So nun hör ich aber auf sonst wird das ganz so verwirrend und eine Themenverfehlung wie Nabils Brainstorming.

Gutes Händchen, Waldbauernbub

[Waldbauernbub]

Affymetrix neues Kursziel
Think Equity Partners

Die Analysten vom Investmenthaus Think Equity Partners stufen die Aktie von Affymetrix (ISIN US00826T1088/ WKN 901198) unverändert mit „equal weight“ ein, senken aber das Kursziel von 32 auf 25 US-Dollar.

Erst kürzlich habe man die Einschätzung der Aktie reduziert, um Bedenken im Hinblick auf die Auftragssituation Rechnung zu tragen.

Nach der Warnung könnte die Aktie bis Jahresende wieder zu einem Kursniveau im unteren 20 USD-Bereich zurückkommen, was auf eine Erholung des Umsatzwachstums und neue Produktangebote gestützt werden dürfte. Nichtsdestotrotz bleibe die Aktie derzeit hochspekulativ.

Vor diesem Hintergrund bewerten die Analysten von Think Equity Partners die Aktie von Affymetrix weiterhin mit dem Votum „gleichgewichten“.

[Waldbauernbub]

Nun ja soviel dazu

[sukashi]

denke etwa in diesselbe richtung.
affymetrix wird sich wieder in alte höhen begeben-
nicht sofort aber langsam und dafür sicher...

gruss
sukashi

[Isabartels]

Bin gestern zu 15,55€ eingestiegen, da ich jetzt doch langsam mit einem Rebound rechne.

[timerprofi]

@ Isa

Hallo Isa bin auch mit 15,40.- dabei !!

Frohe Ostern - Timerprofi

[Isabartels]

Hallo Timer,
prima. Hast Du auch noch Medx?
Ebenfalls schöne Ostern und dass wir mit Affymetrix viel Erfolg haben.
Gruss
Isa

[timerprofi]

@ Isa

Medx hab ich momentan nicht mehr, schaue mir den Wert aber laufend an.( 883040 )
Bin momentan auch bei Pacific Internet dabei ( 918895 ) habe schon gute Gewinne realisiert.

Und hoffe auch auf Icos ( 882008 )

Bis bald .....am Montag gehts ja in Übersee schon los.

[otc_trader]

Re Affymetrix:
Das Drama zeichnete sich schon am 19.3.03 ab. Gekennzeichnet durch einen "Hanging Man" auf Schlusskursbasis. Ein kleinerer "Hanging Man" nochmals am 27.3.03.
Ein möglicher unterer Umkehrpunkt zeichnet sich durch einen "Inverted Hammer" vom 17.4.03 ab.

[timerprofi]

@ otc

Und das heisst Kursziel für nächste Woche 20.- Usd.
oder liege ich da falsch ????

[otc_trader]

@ #10
schätze 17,50 - 18,00 USD.
10-Tage EMA liegt bei 18,70
und nächster Widerstand bei 20,80.

[Bulle Mario]

Heute ist wohl der beste Kauftag seit dem Crash...

Branchenprimus Amgen meldet geniale Zahlen(Umsatz plus 76 %), die die ganze Branche beeinflussen können!

Die Biotechs haben die vergangene Rallye fast komplett verschlafen.

...und Affx macht erste Anstalten sich von den Tiefs zu lösen.

We´ll see

Aktuell 15,80

BULLE

[Bulle Mario]

AFFX veröffentlicht heute nachbörslich Zahlen (Est EPS -0,02)...

Nach der Gewinnwarnung sollte die Prognose wohl geschlagen werden! und dann...

aktuell 16,20

BULLE

[Bulle Mario]

Island kippt- Ausbruchsgefahr bei weiterer Bestätigung!

[Bulle Mario]

Da ist der Ausbruch auch schon ...

[Bulle Mario]

Gibt es eine genauere Vorhersage?

aktuell 16,50

BULLE

[Bulle Mario]

naja...

Affymetrix first-quarter loss widens
WEDNESDAY, APRIL 23, 2003 4:19 PM
- Reuters U.S. Company News

LOS ANGELES, April 23 (Reuters) - Affymetrix Inc. (AFFX) on Wednesday said its first-quarter net loss widened after warning earlier this month that results would fall short due to cautious capital spending in the academic and biotech sectors.

Affymetrix, which makes chips used for genetic research, posted a net loss of $12.7 million, or 22 cents a share, compared with a net loss of $3.6 million, or 6 cents, a year earlier. Results in the latest quarter included $10.1 million, or 17 cents a share, related to a previously announced charge associated with a licensing agreement.

Revenue fell to $66.8 million, including $2.5 million in wafer sales to a subsidiary company, from $68.1 million in the first quarter of 2002, which included $6.0 million in sales to the subsidiary.

For the second quarter, the company projected revenue of $62 million to $65 million and net income per share of 1 cent to 3 cents. For 2003, the company said it expects product and product related revenue of $280 million to $285 million, and total revenue of $295 million to $305 million.

[panik]

Affymetrix Announces GeneChip(R) CustomSeq(TM) SARS Pathogen Detection And Resequencing Array
Tuesday May 6, 7:01 am ET
New GeneChip Array Designed to Identify SARS Virus and Detect Mutations In Its Genome


SANTA CLARA, Calif., May 6 /PRNewswire-FirstCall/ -- Affymetrix, Inc., (Nasdaq: AFFX - News) today announced it is taking orders for its new GeneChip® brand CustomSeq(TM) SARS Pathogen Detection Resequencing Array, designed to enable scientists to rapidly resequence different isolates of the virus that causes SARS and better understand variations associated with the spread of the virus and increased virulence.
ADVERTISEMENT


The new array resequences the entire 29,700 base pairs in the SARS virus and was designed using sequence from public health centers in Canada, the United States and Asia. This product joins a growing list of pathogen arrays developed by Affymetrix.

"SARS has quickly become a major health concern, but by working together and using state-of-the-art genomic technology, researchers have rapidly learned a great deal about this disease," said Greg Yap, Senior Marketing Director, DNA Analysis, at Affymetrix. "We hope that by getting this powerful CustomSeq array into the hands of scientists, we can contribute to understanding SARS and the search for treatments."

Researchers are expected to use the CustomSeq SARS array in several ways. First, by determining DNA sequence variation among SARS samples, scientists can categorize different isolates of the virus into subtypes. Second, by comparing patient outcome with the pathogen subtypes, scientists may better understand which strains are most dangerous and discover key factors in developing therapies. Third, epidemiologists can use the CustomSeq SARS array to study how the virus is evolving over time, during its spread into different geographies and populations.

Investigating pathogens and viruses is one of many CustomSeq array applications. Other potential uses include SNP discovery, comparative sequencing of drug targets and investigation of candidate gene regions. One CustomSeq array can sequence about 30,000 bases of unique sequence quickly and with a high degree of accuracy. Compared to capillary sequencing, CustomSeq arrays make researchers faster and more effective by delivering completed sequence with minimal assembly, alignment, and curation. CustomSeq arrays also feature a simple assay protocol that makes sample preparation more efficient.

For more information about the SARS array, customers may contact their Affymetrix Sales Representative, or point their browsers to www.affymetrix.com.

About Affymetrix:

Affymetrix is a pioneer in creating breakthrough tools that are driving the genomic revolution. By applying the principles of semiconductor technology to the life sciences, Affymetrix develops and commercializes systems that enable scientists to improve the quality of life. The Company`s customers include pharmaceutical, biotechnology, agrichemical, diagnostics and consumer products companies as well as academic, government and other non-profit research institutes. Affymetrix offers an expanding portfolio of integrated products and services, including its integrated GeneChip platform, to address growing markets focused on understanding the relationship between genes and human health. Additional information on Affymetrix can be found at www.affymetrix.com.

All statements in this press release that are not historical are "forward- looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix` "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements, are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to, risks of the Company`s ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses, market acceptance (including market acceptance of the GeneChip SARS CustomSeq Array), personnel retention, uncertainties relating to the length and severity of the current global economic weakness, the reduction in overall capital spending in the academic and biotechnology sectors, changes in government funding policies, unpredictable fluctuations in quarterly revenues, uncertainties related to cost and pricing of Affymetrix products, dependence on collaborative partners, uncertainties relating to sole source suppliers, uncertainties relating to FDA, and other regulatory approvals, competition, risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix` Form 10-K for the year ended December 31, 2002 and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix` expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

NOTE: Affymetrix, the Affymetrix logo and GeneChip are trademarks owned or used by Affymetrix, Inc. CustomSeq is a trademark of Affymetrix, Inc.




--------------------------------------------------------------------------------
Source: Affymetrix, Inc.